Biohit: Difference between revisions
No edit summary |
|||
(37 intermediate revisions by 23 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Finnish biotechnology company}} |
|||
{{Infobox company |
{{Infobox company |
||
| name = Biohit Oyj |
| name = Biohit Oyj |
||
| type = |
| type = [[Julkinen osakeyhtiö]] |
||
| traded_as = {{OMX|HEX24241|BIOBV.B}} |
|||
| founded = {{Start date and age|1988}} |
|||
| founder = Osmo Suovaniemi |
| founder = Osmo Suovaniemi |
||
| location = [[Helsinki]], [[Finland]] |
| location = [[Helsinki]], [[Finland]] |
||
| area_served = Worldwide |
| area_served = Worldwide |
||
| key_people = Osmo Suovaniemi <small>([[Entrepreneur|Founder]] and [[Chairman of the Board]])</small>, Semi Korpela <small>([[President]] and [[Chief Executive Officer|CEO]])</small> |
| key_people = Osmo Suovaniemi <small>([[Entrepreneur|Founder]] and [[Chairman of the Board]])</small>, Semi Korpela <small>([[President (corporate title)|President]] and [[Chief Executive Officer|CEO]])</small> |
||
| |
| num_employees = 40 in Finland, 10 in subsidiaries |
||
| industry = [[Medical equipment]] |
| industry = [[Medical equipment]] |
||
| products = Diagnostics and medical devices (Acetium products for acid free stomach and smoking cessation) |
|||
| products = [[Pipette|liquid handling equipment]] |
|||
| equity = |
| equity = €15.5 million <small>(2019)</small> |
||
| website = {{URL|https://www.biohithealthcare.com/}} |
|||
}} |
}} |
||
'''Biohit Oyj''' is a Finnish company which develops, manufactures, and markets diagnostics products for use in [[research]] and [[health care]]. |
'''Biohit Oyj''' is a Finnish company which develops, manufactures, and markets biotech and diagnostics products for use in [[research]] and [[health care]]. |
||
== |
==Summary== |
||
Biohit was established in 1988 in [[Finland]] by Professor Osmo |
Biohit was established in 1988 in [[Finland]] by Professor Osmo Suovaniemi (M.D., Ph.D.), previously known as the founder of {{ill|Labsystems (Finnish company)|fi|Labsystems|lt=Labsystems}}.<ref>{{Cite journal |author = Harriet Öster |date = 8 October 1998 |title = Labsystems kasvaa suuren suojassa |journal = Tekniikka & Talous |url = http://www.tekniikkatalous.fi/uutiset/article28510.ece |accessdate = 2009-11-15 }}{{Dead link|date=July 2020 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>{{Cite web |title=Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being |author=Osmo Suovaniemi, Helena Hentola |publisher=Biohit |year=2004 |url=http://www.biohit.com/resource/files/media/articles/biohit-innovation-patenting-strategy.pdf |access-date=2013-03-02 |archive-url=https://web.archive.org/web/20111110184424/http://www.biohit.com/resource/files/media/articles/biohit-innovation-patenting-strategy.pdf |archive-date=2011-11-10 |url-status=dead }}</ref> He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit is a globally operating Finnish biotechnology company. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) has been quoted on [[NASDAQ OMX Helsinki]] since 1999, Small cap/Healthcare. Semi Korpela was appointed CEO in 2011. |
||
Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. |
|||
==Markets== |
==Markets== |
||
Biohit's two businesses are acetaldehyde |
Biohit's two businesses are acetaldehyde-eliminating products and diagnostics. More than 90% of Biohit's sales occur outside Finland.<ref name="annual_report_2013">Biohit Oyj. Annual Report 2019</ref> |
||
⚫ | |||
⚫ | The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD) and deficiencies of vitamin B12, calcium and iron. In addition to this, Biohit offers Quick tests for the detection of |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
An acid-free stomach is the primary risk factor in gastric cancer. According to recent research, it is also a significant risk factor in oesophageal cancer. Acetium® is a CE marked product developed and patented by Biohit Oyj. It is intended for persons with a low-acid or anacidic stomach |
|||
⚫ | |||
⚫ | |||
⚫ | The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of ''[[Helicobacter pylori]]'' infection and [[atrophic gastritis]] from a blood sample. They are also ideal tools for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD), and deficiencies of vitamin B12, calcium, and iron. In addition to this, Biohit offers Quick tests for the detection of |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
In 2018 was launched a new, nicotine-free smoking cessation product, Acetium Lozenge. |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests. |
Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests. |
||
===Distribution |
===Distribution network=== |
||
A network of 40 [[distributor]]s, including 2 subsidiaries, in more than 40 countries is selling Biohit products. |
A network of 40 [[distributor]]s, including 2 subsidiaries, in more than 40 countries is selling Biohit products. In the U.S. the official distributor is [https://biotestingsupplies.com/ Bio Testing Supplies], a division of [https://avriogenetics.com/ Avrio Genetics].{{Citation needed|date=January 2015}} |
||
==Research, |
==Research, development, and intellectual property== |
||
Biohit spends roughly 30% of net sales on [[basic research]] each year and pursues an aggressive [[patenting]] strategy.<ref>Reuters. |
Biohit spends roughly 30% of net sales on [[basic research]] each year and pursues an aggressive [[patenting]] strategy.<ref>Reuters. Overview of Biomet Oyj. [https://web.archive.org/web/20141024141219/http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=BIOBV.HE] </ref> |
||
== References == |
== References == |
||
<!--- See [[Wikipedia:Footnotes]] on how to create references using <ref></ref> tags which will then appear here automatically --> |
|||
{{Reflist}} |
{{Reflist}} |
||
== |
==External links== |
||
* |
* {{Official website|https://www.biohithealthcare.com/}} |
||
{{Nasdaq Helsinki}} |
|||
[[Category:Companies established in 1988]] |
[[Category:Companies established in 1988]] |
||
[[Category: |
[[Category:Biotechnology companies of Finland]] |
||
[[Category:Chemical companies of Finland]] |
[[Category:Chemical companies of Finland]] |
||
[[Category: |
[[Category:Companies listed on Nasdaq Helsinki]] |
||
[[Category:Companies listed on the Helsinki Stock Exchange]] |
Latest revision as of 10:58, 5 April 2024
Company type | Julkinen osakeyhtiö |
---|---|
Nasdaq Helsinki: BIOBV.B | |
Industrie | Medical equipment |
Gegründet | 1988 |
Gründer | Osmo Suovaniemi |
Hauptsitz | Helsinki, Finland |
Area served | Worldwide |
Key people | Osmo Suovaniemi (Founder and Chairman of the Board), Semi Korpela (President and CEO) |
Produkte | Diagnostics and medical devices (Acetium products for acid free stomach and smoking cessation) |
Total equity | €15.5 million (2019) |
Number of employees | 40 in Finland, 10 in subsidiaries |
Website | www |
Biohit Oyj is a Finnish company which develops, manufactures, and markets biotech and diagnostics products for use in research and health care.
Summary
[edit]Biohit was established in 1988 in Finland by Professor Osmo Suovaniemi (M.D., Ph.D.), previously known as the founder of Labsystems .[1][2] He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit is a globally operating Finnish biotechnology company. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) has been quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare. Semi Korpela was appointed CEO in 2011.
Markets
[edit]Biohit's two businesses are acetaldehyde-eliminating products and diagnostics. More than 90% of Biohit's sales occur outside Finland.[3]
Diagnostic tests
[edit]The diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD), and deficiencies of vitamin B12, calcium, and iron. In addition to this, Biohit offers Quick tests for the detection of
- Lactose intolerance
- Helicobacter pylori infection
- Celiac disease
- Screening of colorectal cancer
Acetaldehyde binding products
[edit]In 2018 was launched a new, nicotine-free smoking cessation product, Acetium Lozenge.
Monoclonal antibodies
[edit]Biohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for the diagnostic industry.
Instruments
[edit]Adopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests.
Distribution network
[edit]A network of 40 distributors, including 2 subsidiaries, in more than 40 countries is selling Biohit products. In the U.S. the official distributor is Bio Testing Supplies, a division of Avrio Genetics.[citation needed]
Research, development, and intellectual property
[edit]Biohit spends roughly 30% of net sales on basic research each year and pursues an aggressive patenting strategy.[4]
References
[edit]- ^ Harriet Öster (8 October 1998). "Labsystems kasvaa suuren suojassa". Tekniikka & Talous. Retrieved 2009-11-15.[permanent dead link]
- ^ Osmo Suovaniemi, Helena Hentola (2004). "Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being" (PDF). Biohit. Archived from the original (PDF) on 2011-11-10. Retrieved 2013-03-02.
- ^ Biohit Oyj. Annual Report 2019
- ^ Reuters. Overview of Biomet Oyj. [1]